Artiva Biotherapeutics (ARTV) Equity Average (2023 - 2025)
Artiva Biotherapeutics (ARTV) has disclosed Equity Average for 3 consecutive years, with $119.6 million as the latest value for Q4 2025.
- On a quarterly basis, Equity Average fell 38.29% to $119.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $119.6 million, a 38.29% decrease, with the full-year FY2025 number at $148.3 million, up 1104.46% from a year prior.
- Equity Average was $119.6 million for Q4 2025 at Artiva Biotherapeutics, down from $139.1 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $193.8 million in Q4 2024 to a low of -$182.9 million in Q2 2024.
- A 3-year average of $12.8 million and a median of $62.3 million in 2024 define the central range for Equity Average.
- Biggest YoY gain for Equity Average was 2711.04% in 2025; the steepest drop was 38.29% in 2025.
- Artiva Biotherapeutics' Equity Average stood at -$156.7 million in 2023, then surged by 223.66% to $193.8 million in 2024, then crashed by 38.29% to $119.6 million in 2025.
- Per Business Quant, the three most recent readings for ARTV's Equity Average are $119.6 million (Q4 2025), $139.1 million (Q3 2025), and $158.9 million (Q2 2025).